Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an Equal Weight rating on the stock. The firm told investors that it adjusted the price targets in the biotechnology space to take into account its 2026 outlook. Is Celldex Therapeutics, Inc. (CLDX) the Best Cancer Stock to Invest in for Long-Term Gain? In a separate develo ...

Core Viewpoint - Celldex Therapeutics, Inc. (NASDAQ:CLDX) is viewed as a small-cap stock with potential upside, but Barclays has initiated coverage with an Underweight rating and a $25 price target due to safety concerns and competitive pressures [1][3]. Group 1: Company Overview - Celldex Therapeutics, Inc. develops, manufactures, and commercializes novel therapeutics for human health care, with a pipeline that includes Varlilumab, CDX-1140, CDX-301, and CDX-3379 [3]. Group 2: Investment Analysis - Barclays highlighted that while there is binary risk associated with small and mid-cap biotechnology stocks, investments backed by de-risked mechanisms of action and prior clinical data present a favorable risk-reward profile [2]. - The firm noted that the market is currently favorable towards new mechanisms and modes of action that could enhance dosing frequency and patient compliance [2]. Group 3: Clinical Data and Market Position - Despite the encouraging clinical data for Celldex's lead molecule barzolvolimab, the shares are not expected to provide significant upside through 2026 due to safety liabilities and a competitive landscape [3].